INTRODUCTION

The neurobiological mechanisms of responses to antidepressant agents involve alterations in the functions of neurotransmitter systems, especially the serotonergic and noradrenergic systems. The noradrenergic- and serotonergic-specific antidepressant, mirtazapine, has recently been introduced. It seems that mirtazapine works in a different manner to other SSRIs.

Weight gain is one of the commonly reported adverse events after mirtazapine administration. The candidate receptor profiles for weight gain in mirtazapine are considered to involve blocking of the function of the serotonin 2C receptor (5-HT2C) and histamine receptor blocking.

The 5-HT2C gene is located on the X chromosome at q24 and contains six exons and five introns, spanning at least 230 kb of DNA. The 5-HT2C receptor has different transcriptional activity according to the 5-HT2C -759C/T polymorphism.
5-HT2C receptor density and responsiveness is enhanced in experimental models of depression and in humans. The function of 5-HT 2C receptors has been suggested to be abnormal in individuals with depression. Moreover, the 5-HT2C receptor gene has been a major focus of psychopharmacological research regarding weight gain.

The aim of the present study was to examine whether the 5-HT2C -759C/T polymorphism (rs3813929) was associated with weight change and the treatment response to mirtazapine in Korean patients with major depressive disorder (MDD).

METHODS

Subjects

Between 2005 and 2007, three hundred twenty three in- and outpatients with major depressive disorder were recruited by the Pharmacogenomic Research Center for Psychotropic Drugs at the Department of Psychiatry, Korea University College of Medicine. All potential subjects were examined by trained psychiatrists using the Structured Clinical Interview of the fourth revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). All subjects were of the melancholic type. Depression severity was assessed according to the 21-item Hamilton Depression Rating (HAMD21) scale. Only subjects with a minimum HAMD score of 18 were enrolled in the study. During the study period, patients self-administered an initial dose of 15-30 mg of mirtazapine (Remeron, Organon), followed by daily doses of 15-60 mg for up to 8 weeks. The daily dose was determined on an individual basis at the discretion of the investigators. Benzodiazepine was allowed as a co-prescribed drug. At baseline, 323 MDD patients were enrolled. Of 323 patients, the number remaining in the study was 249 at week 1, 202 at week 2, and 172 at week 4; 149 patients completed 8 weeks of mirtazapine treatment.

Responders were defined as subjects who exhibited a decrease of at least 50% in the HAM-D total score after mirtazapine medication. To evaluate specific clusters of depressive symptoms, HAM-D items were grouped according to the following factors, as described by Serretti et al.: core (items 1, 2, 7, 8, 10, 13), sleep (items 4, 5, 6), activity (items 7, 8), psychic anxiety (items 9, 10), and somatic anxiety (items 11, 12, 13).

After written informed consent was obtained, venous blood was drawn from each subject. This study was approved by the ethics committee of the Korea University Medical Center.

DNA analysis

DNA was extracted from peripheral blood, and polymerase chain reaction (PCR) was performed using the following primers: sense, 5’-ATC TCC ACC ATG GGG TCT CGC-3’ and antisense, 5’-CAA TCT AGC CGC TCC AAA GGC-3’. The amplification mixture contained 3 μL of DNA, 15 μL of 2× GC buffer (TaKaRa, Kyoto, Japan), 4 μL of 2.5 mM dNTP, 1 μL of each primer, 8.4 μL of distilled water, and 0.1 μL of Taq

| Genotype | CC | CT | TT | p  |
|----------|----|----|----|----|
| Female   |    |    |    |    |
| N        | 183| 56 | 4  |    |
| Age (yr, mean±SD) | 50.86±14.60 | 53.02±12.19 | 59.25±5.56 | 0.325 |
| Baseline weight | 56.99±8.34 | 56.66±8.59 | 63.03±17.58 | 0.456 |
| Suicide attempt (Y, %) | 17 (9.6) | 2 (3.7) | 0 (0) | 0.317 |
| Family history of depression (Y, %) | 23 (13.0) | 7 (13.5) | 0 (0) | 0.857 |
| Male     |    |    |    |    |
| N        | 75 |    | 5  |    |
| Age (yr, mean±SD) | 49.24±14.17 | 47.8±16.56 | 0.828 |
| Baseline weight | 67.68±10.33 | 65.60±4.09 | 0.692 |
| Suicide attempt (Y, %) | 3 (4.2) | 0 (0) | 0.642 |
| Family history of depression (Y, %) | 14 (19.4) | 0 (0) | 0.276 |

5-HT: serotonin, C: cytosine, T: thymine, yr: years, Y: present
polymerase (5 U/μL; TaKaRa). Samples were amplified using a PCR thermocycler (Takara) for an initial 5 min at 94°C followed by 30 cycles of 30 seconds at 94°C, 25 s at 56°C, and 30 s at 72°C. After a final 7-min extension at 72°C, the reaction was terminated by cooling to 4°C. Amplified DNA was digested with the restriction endonuclease AciI (New England Biolabs, Beverly, MA). The products were electrophoresed on a 3% agarose gel and stained with ethidium bromide; the 128-bp, 92-bp, and 33-bp fragments corresponded to the -759 C allele, and the 161-bp and 92-bp fragments corresponded to the -759 T allele.

**Statistical analyses**

Hardy-Weinberg equilibrium for the 5-HT 2C -759 C/T polymorphism was tested using a χ2 test. The genetic association of the SNP was analyzed using multiple logistic regression and linear regression for categorical data and continuous variables, respectively, controlling for age and gender as covariates. Repeated-measures ANOVAs were performed for each weekly HAMD score in LOCF data. Survival analysis was performed by the method of Kaplan and Meier, and comparisons of response and drop-out by log-rank analysis.

A p ≤ 0.05 was deemed to indicate statistical significance. All statistical analyses were performed using SPSS (version 10.0;

**Table 2.** The change of HAMD scores over time according to 5-HT2C polymorphism in female patients with major depressive disorder

| Scores          | Time  | Genotype* | P     |
|-----------------|-------|-----------|-------|
|                 |       | CC        | CT    | TT    |       |
| Total           | Baseline | 22.80±4.54 | 22.03±4.12 | 25.50±6.75 | 0.065 |
|                 | 1 w   | 16.60±5.43 | 16.86±5.71 | 18.50±3.54 |     |
|                 | 2 w   | 13.78±5.70 | 14.19±6.20 | 18.00±4.24 |     |
|                 | 4 w   | 11.57±5.48 | 13.27±6.77 | 18.00±4.24 |     |
|                 | 8 w   | 11.22±5.57 | 13.54±7.62 | 18.00±4.24 |     |
| Core            | Baseline | 9.31±2.36  | 9.11±2.06  | 10.25±1.26 | 0.286 |
|                 | 1 w   | 7.08±2.42  | 6.97±2.42  | 8.00±2.83  |     |
|                 | 2 w   | 6.16±2.43  | 6.24±2.61  | 7.50±3.54  |     |
|                 | 4 w   | 5.37±2.57  | 5.76±2.57  | 7.50±3.54  |     |
|                 | 8 w   | 5.30±2.55  | 5.84±3.05  | 7.50±3.54  |     |
| Sleep           | Baseline | 3.43±2.06  | 3.39±1.87  | 5.50±1.00  | 0.156 |
|                 | 1 w   | 2.21±1.97  | 2.51±2.17  | 5.50±0.71  |     |
|                 | 2 w   | 1.92±1.97  | 1.86±2.00  | 4.50±2.12  |     |
|                 | 4 w   | 1.45±1.72  | 1.95±1.94  | 4.50±2.12  |     |
|                 | 8 w   | 1.33±1.69  | 2.08±1.98  | 4.50±2.12  |     |
| Activity        | Baseline | 2.88±1.05  | 2.70±1.11  | 3.00±0.00  | 0.253 |
|                 | 1 w   | 2.26±1.07  | 2.11±1.24  | 2.00±1.41  |     |
|                 | 2 w   | 1.97±1.13  | 2.00±1.22  | 2.00±1.41  |     |
|                 | 4 w   | 1.62±1.10  | 1.81±1.20  | 2.00±1.41  |     |
|                 | 8 w   | 1.63±1.04  | 1.76±1.23  | 2.00±1.41  |     |
| Psychic anxiety | Baseline | 3.14±1.30  | 3.29±0.80  | 3.00±1.63  | 0.548 |
|                 | 1 w   | 2.46±1.22  | 2.70±1.18  | 2.50±0.71  |     |
|                 | 2 w   | 2.03±1.12  | 2.22±1.23  | 3.00±0.00  |     |
|                 | 4 w   | 1.89±1.11  | 1.89±1.20  | 3.00±0.00  |     |
|                 | 8 w   | 1.78±1.11  | 2.11±1.51  | 3.00±0.00  |     |
| Somatic anxiety | Baseline | 3.74±1.19  | 3.48±1.19  | 2.50±1.29  | 0.658 |
|                 | 1 w   | 2.90±1.35  | 2.84±1.07  | 1.50±0.71  |     |
|                 | 2 w   | 2.49±1.31  | 2.57±1.09  | 2.00±0.00  |     |
|                 | 4 w   | 2.24±1.27  | 2.46±1.17  | 2.00±0.00  |     |
|                 | 8 w   | 2.16±1.25  | 2.24±1.26  | 2.00±0.00  |     |

Repeated measure ANOVA. Mean± standard deviation. *genotype of 5-HT2C-759C/T. HAMD: Hamilton Depression Rating, ANOVA: analysis of variance
RESULTS

Clinical characteristics of study subjects for the 5-HT 2C -759 C/T polymorphism

Table 1 summarizes patient data for mean age, frequency of suicide attempts, and family history of MDD. For both genders, there were no significant differences in clinical characteristics according to the 5-HT 2C -759 C/T polymorphism. The 5-HT 2C -759C/T polymorphism was in Hardy-Weinberg equilibrium in females (p=0.90).

Association between the 5-HT 2C -759 C/T polymorphism and HAMD21 score in MDD patients

In histograms, the HAMD score seemed normally distributed. First, we evaluated the relationship between the 5-HT 2C -759 C/T polymorphism and baseline HAMD-21 scores in the Korean MDD patients. As shown in Table 2, baseline HAMD-21 scores did not differ according to the 5-HT 2C -759 C/T genotypes or alleles. In female patients with MDD, there was no significant difference in total HAMD score among three genotypes over the 8-week treatment adjusted to baseline HAMD score. There was no significant difference in HAMD subscale score according to allele in repeated measures ANOVA (Table 2). There was no significant difference in response and drop-out according to genotypes using survival analysis (p=0.35).

No significant difference in HAMD change over 8 weeks was found between the two alleles in females (Figure 1). No significant association was found between the 5-HT 2C -759 C/T polymorphism and HAMD score in males.

We used logistic regression to evaluate the relationship between the 5-HT 2C -759 C/T polymorphism and clinical outcome at 8 weeks after initiation of mirtazapine treatment. The 5-HT 2C -759 C/T genotypes and allele distributions were not significantly different between responders and non-responders in a codominant genetic model at 8 weeks (Table 3). In a dominant or recessive genetic model, 5-HT 2C -759 C/T genotypes and allele distributions were not different between responders and non-responders (data not shown). The 5-HT 2C -759 C/T genotypes and allele distributions were not significantly different between remitters and non-remitters in codominant, dominant, and recessive genetic models at 8 weeks (data not shown).

Association between the 5-HT 2C -759 C/T polymorphism and weight gain after mirtazapine treatment in MDD patients

No significant difference in weight at baseline was observ-
ed among the three genotypes. When we evaluated the weight gain at 1, 2, 4, and 8 weeks adjusted to baseline weight using repeated measures ANOVA, no significant association between weight change and 5-HT 2C -759 C/T allele was found in females (Figure 2). No significant association was found between the 5-HT 2C -759 C/T polymorphism and weight change in males.

**DISCUSSION**

The aim of this study was to examine whether the 5-HT 2C receptor -759 C/T polymorphism was associated with weight change or treatment response after mirtazapine administration in MDD patients. We demonstrated that weight change after mirtazapine administration was not significantly different among the three 5-HT 2C -759 C/T genotypes. Several pharmacogenetic studies have examined antipsychotic agent-induced weight gain (e.g., clozapine, risperidone, olanzapine). It has been reported that 759T had protective effects against obesity and diabetes and showed higher transcriptional activity than 759C. However, some results are inconsistent. A possible reason for non-significance in the present study is as follows. It is known that weight gain is mainly attributed to the antihistaminic activity of mirtazapine, including 5-HT 2C receptor blocking. In a rat study, antagonists for specific receptors were shown to increase food intake (e.g., with 5-HT 2C antagonists and the histamine H1 receptor). Thus, polymorphisms on the histaminergic receptor may influence weight gain.

We demonstrated that treatment responses to mirtazapine were not significantly different among the three 5-HT 2C 759 C/T genotypes. Agents that bind to 5-HT2C receptors with a high affinity, such as m-chlorophenylpiperazine, induce dysphoric effects in some depressive illnesses. Conversely, electrophysiological and biochemical data demonstrate that 5-HT 2C receptor antagonists enhance mesocorticolimbic DA function. Thus, 5-HT2C (and -2A) receptor antagonists (e.g., ketanserin and ritanserin) are clinically efficacious antidepressants. Consistent with this result, it was reported that there was no significant association between 5-HT 2C receptor 759 C/T polymorphism and treatment response or weight change during treatment with mirtazapine.

Regarding the potential influence of the 5-HT 2C polymorphism on the psychopathology of major depressive disorder, 5-HT 2C polymorphism was not associated with symptomatology in the present study. Regarding activity associated with the dopamine system, a significant difference in activity subscale scores of the HAMD was found among the three genotypes of the 5-HT 2C receptor 759 C/T polymorphism. Consistent with the present study, no association was found between 5HT 2C and psychopathology, as defined by the four symptomatology factors used in phenotype definition (mania, depression, delusion, disorganization), even when bipolar subjects were analyzed separately.

This study has some limitations. First, although a single gene may affect responses to antidepressants, any single gene likely plays a relatively minor role in a complex process. Moreover, it was recently suggested that weight gain in response to certain drugs is also associated with another polymorphism of the promoter of the 5-HT2CR gene, the -697G/C polymorphism. Thus, further studies are required to investigate the cumulative effect of interactions with other genes. Second, we did not analyze plasma mirtazapine levels, although we made efforts (tablet count checks and detailed interviews by psychiatrists and research nurses) to exclude patients with poor or no drug compliance. Because mirtazapine is mainly metabolized by a P450 enzyme, performing CYP2D6 genotyping would improve the accuracy of the present results. Third, patients did not take regular doses of mirtazapine. This created another confounding factor that might have influenced both response to treatment and weight gain. Fourth, since HAM-D score is based on patients’ answers, the possibility that the response could be misclassified should also be added to the limitations of the present study.

Notwithstanding these limitations, this study is a first step in examining the potential association between 5-HT 2C gene polymorphisms and mirtazapine effects in Korean depressive patients. Few studies have examined the association between the 5HT 2C receptor 759 C/T polymorphism and weight gain in mirtazapine treatment. Finally, identification of other polymorphisms related to 5-HT 2C activity would be useful in clarifying the role of the 5-HT 2C gene in response to mirtazapine administration.

**Acknowledgments**

This study was supported by grants from the Korea Health 21 R&D Project, Ministry of Health, Welfare, and Family, Republic of Korea (A102065, A120064).

**REFERENCES**

1. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15:220-226.
2. Delgado PL, Miller HL, Salomon RM, Licinio J, Heninger GR, Gelenberg AJ, et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 1993;29:389-396.
3. Kasper S, Praschak-Rieder N, Taucher J, Wolf R. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf 1997; 17:251-264.
4. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998;51:267-285.
5. Laimer M, Kramer-Reinstadler K, Rauchenzauner M, Lehner-Schoner T, Strauss R, Engl J, et al. Effect of mirtazapine treatment on body...
composition and metabolism. J Clin Psychiatry 2006;67:421–424.
6. Lappalainen J, Zhang L, Dean M, Oz M, Ozaki N, Yu DH, et al. Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C). Genomics 1995;27:274–279.
7. Xie E, Zhu L, Zhao L, Chang LS. The human serotonin 5-HT2C receptor: complete cDNA, genomic structure, and alternatively spliced variant. Genomics 1996;35:551–561.
8. Buckland PR, Hoogendoorn B, Guy CA, Smith SK, Coleman SL, O’Donovan MC. Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain. Am J Psychiatry 2005;162:613–615.
9. Fone KC, Shalders K, Fox ZD, Arthur R, Marsden CA. Increased 5-HT2C receptor responsiveness occurs on rearing rats in social isolation. Psychopharmacology (Berl) 1996;123:346–352.
10. Iwamoto K, Kato T. RNA editing of serotonin 2C receptor in human postmortem brains of major mental disorders. Neurosci Lett 2003;346:169–172.
11. Cowen PJ. Serotonin receptor subtypes in depression: evidence from studies in neuroendocrine regulation. Clin Neuropharmacol 1993;16(Suppl 3):S6–S18.
12. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia 2000;43:373–376.
13. De Luca V, Mueller DJ, de Bartolomeis A, Kennedy JL. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol 2007;10:697–704.
14. Han O, Hong J. Structured Clinical Interview for DSM-IV Axis I Disorders-Korean Version. Seoul: Hana Medical Publishing; 2000.
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
16. Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry 2004;61:1235–1244.
17. Lee HY, Kim YK. Brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants. Neuropsychobiology 2008;57:194–199.
18. Serretti A, Lorenzi G, Cusin C, Zanardi R, Lattuada E, Rossiini D, et al. SSRIs antidepressant activity is influenced by G beta 3 variants. Eur Neuropsychopharmacol 2003;13:117–122.
19. Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003;160:677–679.
20. Miller DD, Ellingrod VL, Holman TL, Buckley PF, Arndt S. Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005;133B:97–100.
21. Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Lu CT, et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 2006;26:128–134.
22. Ellingrod VL, Perry PJ, Ringold JC, Lund BC, Beaver-Stille K, Fleming F, et al. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005;134B:76–78.
23. Tsai SJ, Hong CJ, Yu YW, Lin CH. -759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002;360:1790.
24. Theisen FM, Hinney A, Bromel T, Heinzel-Gutenbrunner M, Martin M, Krieg JC, et al. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatr Genet 2004;14:139–142.
25. Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeely PM, Szczepanski K, et al. RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology 1997;36:621–629.
26. Lecklin A, Etu-Seppala P, Stark H, Tuomisto L. Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats. Brain Res 1998;793:279–288.
27. Jacobsen FM, Mueller EA, Rosenthal NE, Rogers S, Hill JL, Murphy DL. Behavioral responses to intravenous meta-chlorophenylpiperazine in patients with seasonal affective disorder and control subjects before and after phototherapy. Psychiatry Res 1994;52:181–197.
28. Di Matteo V, De Blasi A, Di Giulio C, Esposito E. Role of 5-HT(2C) receptors in the control of central dopamine function. Trends Pharmacol Sci 2001;22:229–232.
29. Robinson DS. Serotonin receptor subtypes and affective disorders. Clin Neuropharmacol 1993;16(Suppl 3):S1–S5.
30. Baxter G, Kennett G, Blaney F, Blackburn T. 5-HT2 receptor subtypes: a family re-united? Trends Pharmacol Sci 1995;16:105–110.
31. Risselada AJ, Mulder H, Heerdink ER, Grube AM, Wilming FW, Egberts TC. The association between serotonin 2C receptor polymorphisms and weight gain and eating behavior in patients using mirtazapine: a prospective follow-up study. J Clin Psychopharmacol 2010;30:207–209.
32. Serretti A, Lilli R, Lorenzi G, Lattuada E, Smeraldi E. Serotonin-1A receptor genes are not associated with psychotic symptomatology of mood disorders. Am J Med Genet 2000;96:161–166.
33. Godlewksa BR, Olajossy-Hilkesberger L, Ciwoniuk M, Olajossy M, Marmurowska-Michalowska H, Limon J, et al. Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene. Pharmacogenomics 2009;9:234–241.